Industries > Pharma > Global Osteoporosis Pharmaceutical and Nutraceutical Market Report 2020-2030

Global Osteoporosis Pharmaceutical and Nutraceutical Market Report 2020-2030

Forecasts by Type of Pharmaceuticals viz. Antiresorptive (Bisphosphonates, Selective Estrogen Receptor Modulator, Rank Ligand Inhibitors, Parathyroid Hormone and Others), Anabolic and Others, by Type of Nutraceutical (Minerals, Herbs and Phytochemicals, Dairy Products and Others), and Profiles of Leading Companies and Regional and Leading National Market Analysis

PUBLISHED: 01 May 2020
PAGES: 338
PRODUCT CODE: PHA0722
SUBMARKET: Therapeutic Drugs

Clear
WOOCS 2.2.1
SKU: PHA0722 Categories: , Tag:

Osteoporosis – Management of a global Challenge
Osteoporosis is a common disorder that is mostly common in the aging population and post- menopausal women. According to the International Osteoporosis Foundation, osteoporosis affects 1 in 4 women and more than 1 in 8 men over the age of 50 years, with 1 in 4 men and women having evidence of a vertebral fracture. The treatment and management of osteoporosis is a major challenge for healthcare workers and primary care givers. Numerous global and regional companies have been working on the R&D and production of various drugs and natural products called nutraceuticals for the treatment and management of osteoporosis. The Osteoporosis market was estimated to account for USD xxx bn in 2019 and is expected to grow with a CAGR of xxx% between 2020-2025.

To access the data contained in this document please email contactus@visiongain.com

The Osteoporosis Pharma and Nutra Market – Report Deliverables
Our 338-page report that includes 160 tables and 134 figures throws light on the pharmaceutical and nutraceutical market, the current market trends, new product launches, market estimates of the major therapeutic drug like antiresorptive, anabolic and Others with its different types in both global and regional markets. We also focus on the major types of nutraceuticals like minerals, herbals and phytochemicals, dairy products and others that are being widely prescribed and consumed for the management of osteoporosis. The report also includes invaluable insights and into how the COVID-19 pandemic will affect the market in the forecast period.

Global Osteoporosis Pharmaceutical and Nutraceutical Market 2020-2030

Osteoporosis Market – The Scope of the report
The current report is a vision for an array of information from market valuation, market trends, a SWOT of the market, leading regional and global market players and other similar information. Some of the scope includes:

• Market Estimation from 2020-2030 for global and regional market segmented further based on type of osteoporosis drugs, geographical region and countries.

• Market segmented based on the type of drugs
• Pharmaceuticals – It includes antiresorptive drugs which is further segmented into bisphosphonates, SERM, RLI, PH and Others. Major drugs like Fosamax, Boniva, Actonel, Aclasta, Evista, Duavee, Denosumab, Forteo, and many others are covered in the report. The anabolic drug like Evenity is also included in the report. Apart from them, drugs under clinical trials has also been covered in the report.
• Nutraceuticals – It includes the 4 major type of nutraceuticals like minerals, herbals and phytochemicals, dairy products and Others. The report covers 35 essential nutraceuticals like Calcium, Vitamins D, K, curcumin, embelin and others with global estimates forecast to 2030.

• Market segment based on the geographical distribution which includes
• USA
• Europe (UK, Germany, Italy, Spain and France)
• BRIC (Brazil, India, Russia, China)
• Japan
• Rest of the World

• Based on the leading companies
• Eli Lilly
• Amgen
• UCB
• GSK
• Merck and Co.
• Allergan
• Sanofi Aventis
• Pfizer
• Novartis
• Radius Health
• Zbiotics
• Kemin Europa
• Ajinomoto
• Herballife Nutrition
• Pharma Nord

• The report also includes the qualitative analysis (SWOT and STEP) for the osteoporosis pharmaceutical and nutraceutical market which enables the qualitative and quantitative analysis.

To access the data contained in this document please email contactus@visiongain.com

Buy our report today Global Osteoporosis Pharmaceutical and Nutraceutical Market Report 2020-2030: Forecasts by Type of Pharmaceuticals viz. Antiresorptive (Bisphosphonates, Selective Estrogen Receptor Modulator, Rank Ligand Inhibitors, Parathyroid Hormone and Others), Anabolic and Others, by Type of Nutraceutical (Minerals, Herbs and Phytochemicals, Dairy Products and Others), and Profiles of Leading Companies and Regional and Leading National Market Analysis. Avoid missing out by staying informed – order our report now.

Visiongain is a trading partner with the US Federal Government
CCR Ref number: KD4R6

Do you have any custom requirements we can help you with? Any need for specific country, geo region, market segment or specific company information? Contact us today, we can discuss your needs and see how we can help: sara.peerun@visiongain.com

Download sample pages

Complete the form below to download your free sample pages for Global Osteoporosis Pharmaceutical and Nutraceutical Market Report 2020-2030


Download sample pages

Complete the form below to download your free sample pages for Global Osteoporosis Pharmaceutical and Nutraceutical Market Report 2020-2030


Latest Pharma news

Visiongain Publishes Generic Drugs Market Report 2020-2030

The 431-page report provides clear detailed insight into the generic drugs market. Discover the key drivers and challenges affecting the market.

03 July 2020

READ

Visiongain publishes Clinical Workflow Solutions Market Report 2020-2030

Where is the Clinical Workflow Solutions market heading? If you are involved in this sector you must read this newly updated report. Visiongain’s report shows you the potential revenues streams to 2030, assessing data, trends, opportunities and business prospects there.

03 July 2020

READ

Visiongain Publishes Clinical Trials Market Report 2020-2030

With the growing burden of rare diseases around the world, there has been a rise and advancement in the therapy development of these types of diseases. While the fact remains that over 90% of these diseases lack approval for treatment and the total number of terminal rare diseases to receive the first treatment every year remains low.

01 July 2020

READ

Visiongain Publishes Clinical Risk Grouping Solutions Market Report 2020-2030

The market growth is attributed to the growing adoption of big data and AI in data management and monitoring of clinical information in health care.

01 July 2020

READ

Categories

Category